GLYC
GlycoMimetics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.13M
P/E Ratio
—
EPS
$-46.00
Beta
1.60
52W High
$0.00
52W Low
$0.00
50-Day MA
$22.49
200-Day MA
$24.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About GlycoMimetics Inc
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of new glucomimetic drugs to address unmet medical needs resulting from disease in the United States. The company is headquartered in Rockville, Maryland.
Fundamentals
| Revenue (TTM) | 10,000 |
| Gross Profit (TTM) | 10,000 |
| EBITDA | $-23.76M |
| Operating Margin | 0.00% |
| Return on Equity | -182.70% |
| Return on Assets | -74.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.23 |
| Price-to-Book | 300.17 |
| Price-to-Sales (TTM) | 1095.16 |
| EV/Revenue | 555.4 |
| EV/EBITDA | -0.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $64.53M |
| Float | 645,150 |
| % Insiders | 2.66% |
| % Institutions | 47.77% |
Historical Volatility
HV 10-Day
0.00%
HV 20-Day
0.00%
HV 30-Day
0.00%
HV 60-Day
0.00%
HV Rank
—
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GLYC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026